No abstract available
MeSH terms
-
Antibodies, Viral
-
BNT162 Vaccine
-
COVID-19* / prevention & control
-
Humans
-
Immunity
-
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
-
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
-
Prospective Studies
-
RNA, Messenger / genetics
-
SARS-CoV-2
-
T-Lymphocytes
-
Vaccination
Substances
-
Antibodies, Viral
-
RNA, Messenger
-
BNT162 Vaccine
Grants and funding
Funding: this study was supported by grants from the SciLifeLab National COVID-19 Research Program, financed by the Knut and Alice Wallenberg Foundation, the Swedish Research Council, Region Stockholm, the Swedish Blood Cancer Foundation and Karolinska Institutet.